in the itt population, e4(-) participants (n = 55) administered ac-1202 had a significant 4.77 point difference in mean change from baseline in adas-cog scores at day 45 (p = 0.0005) and a 3.36 point difference at day 90 (p = 0.0148) compared to placebo.